Blockchain Registration Transaction Record

GeoVax's Multi-Antigen COVID Vaccine Shows Strong Results in High-Risk Patients

GeoVax's GEO-CM04S1 COVID-19 vaccine shows strong immune responses in immunocompromised patients, outperforming mRNA vaccines in Phase 2 trials with no serious adverse events.

This development is crucial because immunocompromised individuals, such as those with blood cancers or post-transplant status, remain highly vulnerable to COVID-19 despite existing vaccines, which often provide inadequate protection. A more effective vaccine for this population could reduce severe illness, hospitalizations, and deaths, easing healthcare burdens and improving quality of life for millions globally. Additionally, the multi-antigen approach may offer broader and longer-lasting immunity against evolving variants, potentially shaping future pandemic preparedness and vaccine strategies beyond COVID-19.